Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Genfit  /  Genfit 2018

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Genfit PSE:GNFT.FR, FR0004163111

  • 3,255 6 mei 2024 17:35
  • +0,020 (+0,62%) Dagrange 3,235 - 3,335
  • 121.006 Gem. (3M) 110,4K

Genfit 2018

82 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste | Omlaag ↓
  2. [verwijderd] 17 april 2018 15:17

    Genfit Seeks Alliances for Top Drug, Is Open to Takeover: CEO
    2018-04-12 12:00:56.292 GMT

    By Marthe Fourcade
    (Bloomberg) -- Genfit plans to commercialize experimental
    NASH drug elafibranor in some markets like major European
    countries, seek alliances for others like Asia or South America,
    CEO Jean-Francois Mouney says in interview at EASL meeting in
    Paris.
    * Company also wouldn’t object to takeover proposal as long as
    offer is attractive and makes sense from industrial standpoint.
    “We are very open”: Mouney
    * Elafibranor, with potential to reverse NASH as well as help
    reduce cardiovascular risk, is “obvious blockbuster”
    * Medicine is “very strong candidate” for first-line treatment
    of NASH, and possible backbone for combination therapy, which
    matters more than whether it’s first to market, says Dean Hum,
    chief scientific officer
    * Genfit also working on simpler diagnostic test with blood test
    vs current need for liver biopsy; in talks with diagnostic
    companies and aims for regulatory approval in 2020 or 2021: Hum
    * Elafibranor Phase 3 results to be released at end of 2019
    * NOTE: Nov. 22, Genfit Says Safety Board Ruled That NASH Drug
    Test Can Proceed

    To contact the reporter on this story:
    Marthe Fourcade in Paris at mfourcade@bloomberg.net
    To contact the editors responsible for this story:
    Eric Pfanner at epfanner1@bloomberg.net
    Phil Serafino, John J. Edwards III
  6. sp1946 21 april 2018 18:48
    DZR. Natuurlijk weet je het beter dan alle anderen. Toch maar even het lijstje van de adviezen.Ik heb en hou mijn vertrouwen.

    Analyst Coverage
    ANALYST
    RATING
    Ed Arce
    H.C. WAINWRIGHT & CO.
    March 12, 2018
    Buy
    Target Price: €105
    Christophe Dombu
    PORTZAMPARC
    January 23, 2018
    Buy (opinion unchanged)
    Target Price: €69,7
    Yasmeen Rahimi
    ROTH CAPITAL PARTNERS
    December 21, 2017
    Buy
    Target Price: €116
    Jean-Jacques Le Fur
    NATIXIS
    April 26, 2017
    Buy
    Target Price: €45
    Sébastien Malafosse
    ODDO
    March 3, 2017
    Buy (opinion unchanged)
    Target Price: €46
    Arsene Guekam
    KEPLER CHEUVREUX
    March 3, 2017
    Buy (opinion unchanged)
    Target Price: €48
    Fanny Meindre
    CM-CIC Securities
    November 3, 2016
    Target Price: €62
    Suzanne van Voorthuizen
    KEMPEN & CO
    October 11, 2016
    Buy (opinion unchanged)
    Target Price: €64

  7. forum rang 10 DeZwarteRidder 21 april 2018 18:51
    quote:

    sp1946 schreef op 21 april 2018 18:48:

    DZR. Natuurlijk weet je het beter dan alle anderen. Toch maar even het lijstje van de adviezen.Ik heb en hou mijn vertrouwen.

    Analyst Coverage
    ANALYST
    RATING
    Ed Arce
    H.C. WAINWRIGHT & CO.
    March 12, 2018
    Buy
    Target Price: €105
    Christophe Dombu
    PORTZAMPARC
    January 23, 2018
    Buy (opinion unchanged)
    Target Price: €69,7
    Yasmeen Rahimi
    ROTH CAPITAL PARTNERS
    December 21, 2017
    Buy
    Target Price: €116
    Jean-Jacques Le Fur
    NATIXIS
    April 26, 2017
    Buy
    Target Price: €45
    Sébastien Malafosse
    ODDO
    March 3, 2017
    Buy (opinion unchanged)
    Target Price: €46
    Arsene Guekam
    KEPLER CHEUVREUX
    March 3, 2017
    Buy (opinion unchanged)
    Target Price: €48
    Fanny Meindre
    CM-CIC Securities
    November 3, 2016
    Target Price: €62
    Suzanne van Voorthuizen
    KEMPEN & CO
    October 11, 2016
    Buy (opinion unchanged)
    Target Price: €64
    Als fase 3 mislukt is dit allemaal onzin.
  8. [verwijderd] 22 april 2018 11:40
    www.nashbiotechs.com/nash-biotech-ana...

    Well, being the first on the market with a drug considered by specialists as a future first line treatment, ELAFIBRANOR will be on a virgin market segment without any competition, the other drugs in the group heading the race are targeting subsets of patients or a very small but lucrative segment of advanced fibrosis or cirrhosis.

    This would make it the first-line drug available that would be supplemented by other drugs depending on the progress of the disease.

    That would make almost $ 3 billion in sales in 2025, just for the United States. You can go check the interactive projections on the corresponding page of the site.

  9. forum rang 10 DeZwarteRidder 22 april 2018 12:13
    quote:

    Brouya schreef op 22 april 2018 11:40:

    www.nashbiotechs.com/nash-biotech-ana...

    Well, being the first on the market with a drug considered by specialists as a future first line treatment, ELAFIBRANOR will be on a virgin market segment without any competition, the other drugs in the group heading the race are targeting subsets of patients or a very small but lucrative segment of advanced fibrosis or cirrhosis.

    This would make it the first-line drug available that would be supplemented by other drugs depending on the progress of the disease.

    That would make almost $ 3 billion in sales in 2025, just for the United States. You can go check the interactive projections on the corresponding page of the site.
    Totale nonsens...!!
    De resultaten van fase 2 waren zeer slecht, dus fase 3 wordt een grote mislukking.
  11. [verwijderd] 22 april 2018 20:24
    The only thing I can do is to establish long-term scenarios based on realistic, accurate data and established facts.

    So I decided to gather all available public data that I could find on the context of NASH, disease, in treatment strategies, diagnostic techniques. I have also established a database integrating all drug candidates, their mechanisms of action, their side effects, their therapeutic targets, the progress of their clinical studies, published results. 

    As I am not selfish, I share all this data on this site so that everyone can make his own table, his own opinion. I know that polemists will explain to me that it is useless, but their knowledge of the subject is even worse than mine.

    There are some who invest in values based on advice, analysts' publications, or their feeling of the moment. I like to evaluate things by analyzing, projecting, evaluating the potential by myself. 

    Non-alcoholic steatohepatitis is a growing disease, given its progression; we could even speak of a pandemic.

    I compiled all the latest scientific publications to try to assess the prevalence of the disease around the world; it allowed me to approach, country by country the estimated number of sick patients.

    Based on the progress schedule of each drug candidate as well as these estimated prevalence’s, I was able to establish a model evaluating the market share of each drug in each country, as well as the estimated number of patients treated.

    Since NASH is a silent disease, we need to be very cautious about what the patient care rate will be in the future, it should progress very slowly at the beginning and, as it has been for Diabetes, then accelerate further to reach an important rate of care. As an example, my model predicts that in 2025 only 3.5% of Western patients will be treated.

    This study is freely available here as well as links to all results - NASH MARKET STUDY FREE OF ACCESS

    Some find it too optimistic, as long as one can speak of optimism for the treatment of a life-threatening illness. I was very conservative, however, in terms of prevalence rates, care rates and treatment costs.

    As everything is transparent in the proposed model everyone can make their own opinion on the figures used and weight the results in their own way.

    Analysts use superlatives when talking about the future market for NASH treatment by announcing figures between 20 and 40 billion dollars of annual market.

    Some investors question their figures, often sometime not well supported.

    So I preferred to recalculate myself rather than take them for cash, I confirm that the forecast amounts are well over $ 30 billion and more as soon as the Asian market opens, very impacted by the disease.

    The two most advanced companies are INTERCEPT and GENFIT, but a simple analysis of the profile of their two drugs shows that the patient base that will be able to target the ELAFIBRANOR OF GENFIT is much broader than the the OCALIVA of Intercepts’ one because of its several adverse effects.

    But the valuation of GENFIT is the half of Intercepts’ one, and both, even including a risk factor, always present with the Biotechs, are absolutely not correlated to the size of their potential markets.

    Prudent projections show that the turnover of the two drugs could exceed $ 1 billion a year from 2023 and GENFIT could exceed $ 5 billion by 2025.

    All this with only 3.5% of potential patients treated.

    Markets do not believe in miracles (though, when we see bitcoin!),

    And are therefore very cautious about these easy-to-verify figures.

    They do not know the disease, not the actors and doubt the published figures, they overestimate the risks of failure, even if they remain significant, and are under valuating these companies.

    The field is left open to hedge funds that short these values to the slightest rise, and it must be said that the history of the valuation gives them reason and flexibility to continue. The prices therefore fall regularly according to the good will of the speculators.

    Those, who like me, are betting on success, are few!

    But what can we hope if we consider that we bet on the success of the clinical studies of these companies and in particular GENFIT.

    Well, being the first on the market with a drug considered by specialists as a future first line treatment, ELAFIBRANOR will be on a virgin market segment without any competition, the other drugs in the group heading the race are targeting subsets of patients or a very small but lucrative segment of advanced fibrosis or cirrhosis.

    This would make it the first-line drug available that would be supplemented by other drugs depending on the progress of the disease.

    That would make almost $ 3 billion in sales in 2025, just for the United States. You can go check the interactive projections on the corresponding page of the site.

    I tried to calculate the potential net margin of GENFIT for the year 2025 taking into account direct sales in Europe and licenses in the rest of the world and it exceeds $ 2 billion.

    With a PER of 8, very low compared to the figures practiced on the market, it would already imply a valuation 20 times higher than that of today.

    Even if you are skeptical, and want to divide these figures by 2 or even 4, you can see that the valuation gap remains huge.

    So, even if investing in a Biotech presents a risk,  a few months ago, I estimated that , regarding statistics, the percentage of chance of success for ELAFIBRANOR to reach the market is close to 68%. 

    These are just statistics to objectify the risk, but are they taken into account correctly in the current valuation?  I dont think so!

    To me, the most advanced biotechs targeting NASH remains under valuated!

  13. sp1946 23 april 2018 08:37
    langzaam maar zeker:

    GENFIT: Positive Outcome from the 24-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor
    ? Safety data, including adverse events and laboratory data, were reviewed by the Data Safety Monitoring Board (DSMB) which recommended the continuation of the trial without any modifications
    ? Positive outcome, based on a growing number of patients exposed to treatment for longer periods of time, confirms the good safety profile of elafibranor

    Lille (France), Cambridge (Massachusetts, United States), April 23, 2018
  16. [verwijderd] 9 juni 2018 10:25
    NASH players in spotlight on Bristol-Myers Squibb interest

    Jun 8, 2018 • SA Editor Douglas W. House

    Buying has perked up in certain stocks with exposure to non-alcoholic steatohepatitis (NASH) after Bristol-Myers Squibb's (BMY +0.8%) business development chief Paul Biondi said that the company is "actively looking for acquisitions or license opportunities" in fibrotic diseases (per DealReporter).

  17. [verwijderd] 13 juni 2018 09:02
    Postief NASH nieuws de afgelopen 2 weken, alles wat maar positief is gaat als een raket. Beetje een NASH hype.

    Kijk naar Madrigal (fase 2 resultaten) - 200% in 1 week geloof ik en Galmed (fase 2 resultaten) - 150% op 1 dag

    Ondanks dat de resultaten van beide bedrijven niet heel indrukwekkend waren (volgens 'kenners'), maar wel leuk om te zien die koersexplosies.
  20. [verwijderd] 28 juni 2018 09:18
    globenewswire.com/news-release/2018/0...

    GENFIT: New Preclinical Data Shows Elafibranor Inhibits Development of NAFLD/NASH-Related Cancer

    Elafibranor administration prevented liver tumor development in NAFLD/NASH disease models

    Elafibranor showed direct cytostatic properties on a large selection of human tumor cell-lines
82 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!